Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features

Dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA.R-EPOCH) is used for upfront treatment of high-risk diffuse large B cell lymphoma (DLBCL). In this study, we compared the outcomes in patients with high-risk DLBCL who received frontline rituximab, cyco...

Full description

Bibliographic Details
Main Authors: Bhagirathbhai Dholaria, Yenny Alejandra Moreno Vanegas, Nancy Diehl, Aaron C. Spaulding, Sue Visscher, Han W. Tun, Sikander Ailawadhi, Prakash Vishnu
Format: Article
Language:English
Published: Atlantis Press 2020-04-01
Series:Clinical Hematology International
Subjects:
Diffuse large B-cell lymphoma
chemotherapy
outcomes research
combined antineoplastic chemotherapy protocols
Online Access:https://www.atlantis-press.com/article/125938832/view

Internet

https://www.atlantis-press.com/article/125938832/view

Similar Items